Fewer than half of White evangelical Protestants say benefits of the COVID-19 vaccines outweigh the risks

Home Research Topics Science Science Issues Medicine & Health COVID-19 & Science

May 12, 2023

Appendix B: Detailed charts on views of COVID-19

Fewer than half of White evangelical Protestants say benefits of the COVID-19 vaccines outweigh the risks

Download

Fewer than half of White evangelical Protestants say benefits of the COVID-19 vaccines outweigh the risks

← Prev Page

1 2 3 4 5 6 … 8

Appendix B: Detailed charts on views of COVID-19
Views on benefits and risks of COVID-19 vaccines differ by education, income
Democrats far more likely than Republicans to say benefits of COVID-19 vaccines outweigh the risks
Fewer than half of White evangelical Protestants say benefits of the COVID-19 vaccines outweigh the risks
36% of White evangelical Protestants say they have not received a COVID-19 vaccine
Among Democrats, differences by race and ethnicity in COVID-19 vaccination status
One-in-five Black adults very concerned about a serious case of COVID-19
20% of Hispanic adults very concerned about a serious of case of COVID-19
Those with lower incomes express more concern about getting a serious case of COVID-19

901 E St. NW, Suite 300
Washington, DC 20004
USA
(+1) 202-419-4300 | Main
(+1) 202-857-8562 | Fax
(+1) 202-419-4372 | Media Inquiries

Research Topics

ABOUT PEW RESEARCH CENTER Pew Research Center is a nonpartisan, nonadvocacy fact tank that informs the public about the issues, attitudes and trends shaping the world. It does not take policy positions. The Center conducts public opinion polling, demographic research, computational social science research and other data-driven research. Pew Research Center is a subsidiary of The Pew Charitable Trusts, its primary funder.

Topics

Regions & Countries

Formats

Appendix B: Detailed charts on views of COVID-19

Fewer than half of White evangelical Protestants say benefits of the COVID-19 vaccines outweigh the risks

Download

Post Infographics

Research Topics

Follow Us